cas 441797-42-8|| where to buy N-[5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide

Produktname:N-[5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide

IUPAC Name:benzyl({[5-(4-bromophenyl)-6-chloropyrimidin-4-yl]sulfamoyl})amine

: CAS：441797-42-8; Molekulare Formel：C17H14BrClN4O2S; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM337693-100mg	in stock	șșƻ
CM337693-250mg	in stock	ƻƻƏ
CM337693-1g	in stock	ƅƅş

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 441797-42-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:441797-42-8; Molekulare Formel:C17H14BrClN4O2S; Schmelzpunkt:-; SMILES-Code:O=S(NCC1=CC=CC=C1)(NC2=NC=NC(Cl)=C2C3=CC=C(Br)C=C3)=O; Dichte:

: Katalognummer:CM337693; Molekulargewicht:453.74; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Aprocitentan; New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023.
Aprocitentan is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
A new drug application (NDA) for aprocitentan was accepted for review by the US FDA.